Developed by Ipswich Hospital NHS Trust and Ipswich and East Suffolk Clinical Commissioning Group. Joint formulary - Ophthalmology
|
|
- Jade Simmons
- 5 years ago
- Views:
Transcription
1 Developed by Ipswich Hospital NHS Trust and Ipswich and East Suffolk Clinical Commissioning Group. Document type and title: Joint formulary - Ophthalmology Authorised document folder: New or replacing and existing document: Version number: 3.0 S:\Ipswich&East Suffolk CCG\Medicines Management\QIPP workstreams\joint formulary Replacing existing document Approving body: IESCCG Prescribing Workstream Ipswich Hospital Medicines Management Committee (IHT MMC) Date approved: IESCCG Prescribing Workstream: 05/05/15 IHT MMC: 08/05/15 Implementation date: 11/05/15 Author(s): Committee/ group/ individual responsible for updating this document Review date: July 2016 Medicines management pharmacist IESCCG and formulary pharmacist Ipswich Hospital Authors Revision History Version Date Initials Changes marked /2014 CB/RD N/A /2015 CB N/A /2015 CB Yes /2015 CB No Linked Documentation Document title Document file path Primary care formulary S:\Ipswich&East Suffolk CCG\Medicines Management\QIPP workstreams\primary care formulary work Ipswich Hospital Medicines Formulary Distribution Who to Via Date Version GP prescribing leads Workshare 01/ IHT MMC Meeting 01/ IHT formulary pharmacist 04/15 2.1
2 Joint formulary Prescriptions should be written generically unless a specific brand is recommended in the formulary below (will be shown in italics). Excipient intolerances should be included on the prescription If a preservative free eye preparation is required, please specify the rationale in the clinic letter/patient notes. Requests for preservative free products may be questioned if no rationale is provided. NB. The Ipswich Hospital pharmacy will substitute branded prescriptions for generic medication where it is available and more cost effective. Key Italics Most cost effective brand. (OTC) Item available to purchase over the counter from pharmacies and/or supermarkets Bold First choice based on available evidence and cost effectiveness Version: 3.0 Last updated: May 2015 Next review: July 2016 (or sooner if necessary) BNF section Drugs group Formulary Choices Notes 11 Eye Number of per bottle: Bottle size 2.5ml 5ml 10ml Approximate number of contained If patient has difficulty administering eye, consider co-prescribing an Opticare eye drop dispenser Unlicensed food supplements such as I-Caps etc. for age related macular degeneration should not be prescribed on the NHS Anti-infective eye preparations Antibacterials Chloramphenicol 0.5% eye (OTC) Chloramphenicol 1% eye ointment (OTC) Fucidic acid 1% gel Ciprofloxacin 0.3% eye Levofloxacin 0.5% eye Available OTC for patients over 2 years old Available OTC for patients over 2 years old Levofloxacin 0.5% preservative. free eye Antivirals Aciclovir 3% eye ointment 11.4 Corticosteroids and other anti-inflammatory preparations Corticosteroids Prednisolone 0.5% eye Betamethasone 0.1% eye/ear/nose (Vistamethasone ) Betamethasone 0.1% eye ointment Dexamethasone 0.1% eye (preservative free)
3 Other antiinflammatory preparations Fluorometholone eye (FML) Dexamethasone 0.1% single use eye (Dropodex ) Maxitrol eye Maxitrol eye ointment Rimexolone 1% eye Loteprenol eye Dexamethasone intravitreal Implant Fluocinolone acetonide intravitreal implant Sodium cromoglicate 2% eye (OTC) Nedocromil 2% eye Olopatadine 1mg/ml eye As per NICE TA229. As per NICE TA Mydriatics and cycloplegics Antimuscarinics Cyclopentolate 0.5% eye Cyclopentolate 1% eye Cyclopentolate 1% single use Tropicamide 1% single use Tropicamide 0.5% single use Atropine 1% eye Sympathomimetics Phenylephrine 2.5% single use 11.6 Treatment of glaucoma Phenylephrine 10% single use Beta-blockers Timolol 0.25% eye Prostaglandin analogues and prostamides Betaxolol 0.5% eye Timolol 0.1% unit dose eye (Tiopex ) Latanoprost 50mcg/ml eye Latanoprost preservative free eye (Monoprost ) Travoprost 40mcg/ml eye Bimatoprost 100mcg/ml. Reserved for or with poor compliance.. Reserved for.. Bimatoprost 300mcg/ml single. Reserved for use eye. Sympathomimetics Brimonidine 0.2% eye Carbonic anhydrase inhibitors and systemic drugs Dorzolamide 2% eye Brinzolamide 10mg/ml eye Acetazolamide tablets Acetazolamide injection. Reserved for patients intolerant of dorzolamide Hospital only Dorzolamide 2% unit dose eye. Reserved for Miotics Pilocarpine 1% eye Combination preparations Pilocarpine 2% eye Pilocarpine 2% single use Dorzolamide /timolol 2%/0.5% eye Latanoprost /timolol 50mcg/ml/0.5% eye
4 Brimonidine / Timolol 0.2%/0.5% eye Brinzolamide / timolol 10mg/ml/0.5% eye Bimatoprost / timolol 300mcg/ml/0.5% eye Travoprost /timolol 40mcg/ml/0.5% eye Dorzolamide /timolol 2%/0.5% single use eye 11.7 Local anaesthetics Oxybuprocaine 0.4% single use eye Proxymetacaine 0.5% single use eye Tetracaine 1% single use eye Lidocaine and fluorescein single use eye 11.8 Miscellaneous ophthalmic preparations Hypromellose 0.3% eye (OTC) Polyvinyl alcohol 1.4% eye (OTC) (Snotears ) Tear deficiency, ocular lubricants, and astringents Ocular diagnostic and peri-operative preparations and photodynamic treatment Carbomer % (OTC) Liquid paraffin eye ointment (OTC) Carmellose 1% single use eye (OTC) Carmellose 0.5% single use eye (OTC) Sodium chloride 5% preservative free eye / eye ointment [unlicensed special] Acetylcholine intra-ocular irrigation Aflibercept intravitreal injection Apraclonidine 0.5% eye Apraclonidine 1% single use eye Arceole Bevacizumab Injection Brilliant Peel Densiron 68 heavier-than-water endotamponade EasyGas C 2 F 6 pre-mixed syringes EasyGas C 3 F 8 pre-mixed syringes EasyGas SF6 pre-mixed syringes Fluorescein 1% singe use eye. Reserved for Clinitas Carbomer Gel eye is a cost effective brand Xailin Night is a cost effective brand. For night time use. Preservative free Melophthal is a cost effective brand. Each unit of Melophthal is re-sealable and may be used for up to 12 hours. Usual supply one box per month. Preservative free. Xailin Fresh 0.5% is a cost effective brand. Preservative free. As per NICE TA 294, TA305. Hospital use only. Various strengths. Only to be used when other agents not appropriate Off label special available from Moorfields.
5 Fluorescein 2% single use eye Flurbiprofen 0.03% eye Ketorolac 0.5% eye Ocriplasmin intrvitreal injection Ranibizumab intravitreal injection Vioron* As per NICE TA 297. Hospital only use As per NICE TA155, TA298, TA274, TA283. Joint formulary new drug requests Requests for new drugs from Ipswich Hospital (consultants only) please complete the Ipswich Hospital new drug submission form (available on hospital intranet) Requests for new drugs from primary care please complete the IESCCG new medication request form (available on the IESCCG website) Feedback Please send any feedback or comments to: Ipswich Hospital: Primary care:
BNF CHAPTER 11: EYE 1 January 2018
BNF CHAPTER 11: EYE 1 BNF 11.3.1 ANTIBACTERIALS First Choice. Broad spectrum. Chloramphenicol 0.5% Eye Drops Administration Alternative Administration Eye drops, apply 1 drop at least every 2 hours then
More information11.Eye Administration of drugs to the eye. Eye drops. Eye ointments. Prescribing of Unlicensed Eye Products
1 11.Eye 11.1 - Administration of drugs to the eye Eye-drop dispenser devices (Compleye, Opticare, Opticare Arthro 5, Opticare Arthro 10) are available to aid the instillation of eye drops from plastic
More information11.Eye Administration of drugs to the eye. Eye drops. Eye ointments. Prescribing of Unlicensed Eye Products
1 11.Eye 11.1 - Administration of drugs to the eye Eye-drop dispenser devices (Compleye, Opticare, Opticare Arthro 5, Opticare Arthro 10) are available to aid the instillation of eye drops from plastic
More information11 Eye. To be used in conjunction with NICE guidance/guidelines, the British National Formulary for adults and/or children, and
11 Eye To be used in conjunction with NICE guidance/guidelines, the British National Formulary for adults and/or children, and The Royal College of Ophthalmologists guidelines Index 11.1 Administration
More informationOphthalmic Special Order Products, General Principles
Ophthalmic Special Order Products, General Principles When clinically appropriate and available, licensed products should always be prescribed and dispensed in preference to unlicensed products. Certain
More informationOphthalmic Special Order Products, General Principles
Ophthalmic Special Order Products, General Principles When clinically appropriate and available, licensed products should always be prescribed and dispensed in preference to unlicensed products. Where
More informationDrugs That May Be Used by Certain Optometrists
Drugs That May Be Used by Certain Optometrists Approved drugs. (a) Administration and prescription of pharmaceutical agents. Optometrists who are certified to prescribe and administer pharmaceutical agents
More informationSouth East London Area Prescribing Committee Chronic Open Angle Glaucoma and Ocular Hypertension Treatment Pathway
Proceed to 2 nd line treatment if further reduction in IOP required and there is good response to PGAs or (& no South East London Area Prescribing Committee Chronic Open Angle Glaucoma and Ocular Hypertension
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
Guidelines for the medical treatment of chronic open angle glaucoma and ocular hypertension Summary: DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Diagnosis and management of ocular hypertension (OHT)
More informationEast and North Hertfordshire treatment pathway for primary open angle glaucoma and ocular hypertension in adults
East and North Hertfordshire treatment pathway for primary open angle glaucoma and ocular hypertension in adults Introduction Glaucoma is a group of eye diseases causing optic nerve damage. In most cases
More informationVolume 9; Number 6 May 2015 PRESCRIBING FOR CHRONIC OPEN ANGLE GLAUCOMA (COAG) AND OCULAR HYPERTENSION (OHT)
Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 May 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 May 2008 COSOPT 20 mg/5 mg/ml, eye drops, solution in single dose container Box of 60 0.2 ml single dose containers
More information11 Eye. regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Recommendations from the Lothian Formulary Committee (FC) following Scottish Medicines Consortium (SMC) advice, NICE MTA advice, (FAF3) unlicensed and off-label medicines and (FAF2) medicines not considered
More information11 Eye. systemic disease or both eyes are affected (or 1 eye is affected if the second eye has poor visual acuity) and
Recommendations from the Lothian Formulary Committee (FC) following Scottish Medicines Consortium (SMC) advice, NICE MTA advice, (FAF3) unlicensed and off-label medicines and (FAF2) medicines not considered
More informationOCULAR PHARMACOLOGY GLAUCOMA. increased intraocular pressure. normally mm Hg. when to Tx no fixed level.
OCULAR PHARMACOLOGY GLAUCOMA increased intraocular pressure normally 12 20 mm Hg. when to Tx no fixed level. literature sets ~21 mm Hg as upper limit of normal. some safe at 30 mm Hg some may have damage
More informationVI.2.2 Summary of treatment benefits
EU-Risk Management Plan for Bimatoprost V01 aetiology), both OAG and ACG can be secondary conditions. Secondary glaucoma refers to any case in which another disorder (e.g. injury, inflammation, vascular
More informationA. Incorrect! Acetazolamide is a carbonic anhydrase inhibitor given orally or by intravenous injection.
Pharmacology - Problem Drill 20: Drugs that Treat Glaucoma Question No. 1 of 10 1. is a topical carbonic anhydrase inhibitor. Question #01 (A) Acetazolamide (B) Clonidine (C) Dorzolamide (D) Apraclonidine
More informationCLINICAL OPHTHALMIC THERAPEUTIC PHARMACEUTICAL AGENTS (TPA) QUICK REFERENCE GUIDE
F- 15 CLINICAL OPHTHALMIC THERAPEUTIC PHARMACEUTICAL AGENTS (TPA) QUICK REFERENCE GUIDE Assembled by: Tim Maillet, OD, BSc NSAO Practice Innovations Committee Chairperson September 2009 F- 16 Ocular Allergies
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Epidemiology of the disease Incidence and prevalence Increased pressure in the eye occurs in more than 100 million people, and
More informationDQSA Listening Session June 6, 2017
DQSA Listening Session June 6, 2017 I am Allison Madson, manager of regulatory affairs, for the American Society of Cataract and Refractive Surgery. ASCRS is a medical specialty society representing nearly
More informationPATIENT CASE HISTORY. General Health Medications Allergies
OCULAR PHARMACOLOGY What I Need to Know Before I Medicate A Patient Lynn Lawrence, CPOT, ABOC, COA ROLE of the ASSISTANT AND TECHNICIAN Accurate documentation/recording Patient Education can assist in
More informationA Compendium of Product information & Indicative manufacturer s prices
A Compendium of Product information & Indicative manufacturer s prices (March 2012) for 28-days treatment with commonly used -free eye drops & ointments This information has been produced for prescribing
More informationACETAZOLAMIDE (a-seet-a-zole-a-mide)
EYES Medicines for glaucoma Other medicines for glaucoma Active ingredients (generic names) ACETAZOLAMIDE (a-seet-a-zole-a-mide) Common brands include: Diamox, Glaumox What it is used for Acute glaucoma
More informationDry injection list 1-Ceftriaxone 1000 mg & Sulbactam 500 mg Inj. 2-Ceftriaxone 500 mg & Sulbactam 250 mg Inj.
Dry injection list 1-Ceftriaxone 1000 mg & Sulbactam 500 mg Inj. 2-Ceftriaxone 500 mg & Sulbactam 250 mg Inj. 3-Ceftriaxone 250mg & Sulbactam 125mg Inj. 4-Ceftriaxone 125mg & Sulbactam 62.5mg Inj. 5-Rabeprazole
More informationBNF/BNFC Chapter 11 Eye
NF/NF hapter 11 ye irections for questions 1 to 8. ach of the questions or incomplete statements in this section is followed by five suggested answers. Select the best answer in each case. 1. Which of
More informationChapter 12 Ear, Nose and Oropharynx
Chapter 12 page number 1 Chapter 12 Ear, Nose and Oropharynx First line drugs Drugs recommended in both primary and secondary care Second line drugs Alternatives (often in specific conditions) in both
More informationIntravitreal Injection
for patients Eye Clinic Ipswich Hospital Tel: 01473 703230 Intravitreal Injection What is an intravitreal injection? An intravitreal injection is the injection of a drug into the vitreous body (the jelly
More informationLong Term Care Formulary RS 14. RESTRICTED STATUS Topical Medical Treatment of Glaucoma 1 of 5
RESTRICTED STATUS Topical Medical Treatment of Glaucoma 1 of 5 PREAMBLE Significance: Glaucoma occurs in 1-2% of white people aged over 40 years, rising to 5% at 70 years and exponentially with advancing
More informationMECS and Prescribing. Jane Bell BSc FCOptom, DipTpIP, Dip Glauc
MECS and Prescribing Jane Bell BSc FCOptom, DipTpIP, Dip Glauc Discussion House Rules Open discussion with everyone participating Respect the view of others; do not criticise or judge There are no right
More informationWriting a PBS-RPBS prescription authorised optometrists
Writing a PBS-RPBS prescription authorised optometrists www.medicareaustralia.gov.au Writing a PBS prescription authorised optometrists PBS items you are able to prescribe as an authorised optometrist
More informationREFERENCE GUIDE FOR OPHTHALMIC PREPARATIONS AVAILABLE FOR USE BY ALL OPTOMETRISTS*
APPENDIX III REFERENCE GUIDE FOR OPHTHALMIC PREPARATIONS AVAILABLE FOR USE BY ALL OPTOMETRISTS* *Excluding preparations for use in the treatment of dry eye 1 Antazoline Sulphate (P) For the temporary relief
More informationAbbreviated Update: Ophthalmic Glaucoma Agents
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Abbreviated Update: Ophthalmic Glaucoma Agents Month/Year
More informationData from the recent therapeutic
Getting started in therapeutics Part 8a What drugs will I prescribe and supply? Continuing our series on therapeutics in practice, Lucy Titcomb and Professor John Lawrenson review the range of ophthalmic
More informationMedical Treatment in Pediatric Glaucoma
Medical Treatment in Pediatric Glaucoma By Nader Bayoumi, MD Lecturer of Ophthalmology Ophthalmology Department Alexandria University Alexandria, Egypt ESG 2012 Pediatric glaucoma is a surgical disease
More informationTA Number. TA Link. Annotation
Report generated from BNF with QVH Formulary provided by FormularyComplete (www.pharmpress.com). Accessed 09 10 2015 Title Formulary Status Section TA Number TA Link Annotation Almond Oil 12.1 Drugs acting
More informationMiotics, Glaucoma Meds, Antibiotics, Corticosteroids, NSAIDS Antivirals, Antihistamines Christopher J. McDevitt, M.D.
Miotics, Glaucoma Meds, Antibiotics, Corticosteroids, NSAIDS Antivirals, Antihistamines Christopher J. McDevitt, M.D. Direct agonists Indirect agonist Antagonist Direct agonist: Miosis, accomodation
More information4/24/2018. Miotics, Glaucoma Meds, Antibiotics, Corticosteroids, NSAIDS Antivirals, Antihistamines Christopher J. McDevitt, M.D.
Miotics, Glaucoma Meds, Antibiotics, Corticosteroids, NSAIDS Antivirals, Antihistamines Christopher J. McDevitt, M.D. Direct agonists Indirect agonist Antagonist Direct agonist: Miosis, accomodation Increase
More informationOPHTHALMIC MEDICATIONS
OPHTHALMIC MEDICATIONS Ally Cuddy, PharmD PGY1 Pharmacy Resident September 7, 2017 AMERICAN ACADEMY OF OPHTHALMOLOGY American Academy of Ophthalmology. 2015. CASE #1 TR is a 76 YOM with no significant
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal. Aflibercept for treating diabetic macular oedema.
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Aflibercept for treating diabetic macular oedema Final scope Final remit/appraisal objective To appraise the clinical and cost
More informationMartindale Pharma is a UK pharmaceutical manufacturing company supplying niche products to over 50 countries worldwide.
INTERNATIONAL Martindale Pharma is a UK pharmaceutical manufacturing company supplying niche products to over 50 countries worldwide. Our vision Making Lives Better drives every action and decision of
More informationOPR OPTOMETRIC PRACTICE REFERENCE STANDARDS OF PRACTICE
OPR OPTOMETRIC PRACTICE REFERENCE The best eye health and vision for everyone in Ontario, through excellence in optometric care. Publishing History The Guide to the Clinical Practice of Optometry FIRST
More information2019 Catalog Hospital and Ophthalmology Products and Services
209 Catalog Hospital and Ophthalmology Products and Services Ophthalmology Ophthalmology Services. No prescription required No minimum order quantity New formulations are continually added to our portfolio.
More informationChapter 12 Ear, Nose and Oropharynx
Chapter 12 page number 1 Chapter 12 Ear, Nose and Oropharynx First line drugs Drugs recommended in both primary and secondary care Second line drugs Alternatives (often in specific conditions) in both
More informationPurpose of the Guideline
Trust Policy and Procedure Substitution of Medicines Policy Document ref. no: PP(17)210 For use in: For use by: For use for: Document owner: Status: All clinical areas Pharmacists and authorised Pharmacy
More informationTreatments for Open-Angle Glaucoma. A Review of the Research for Adults
Treatments for Open-Angle Glaucoma A Review of the Research for Adults Is This Information Right for Me? Yes, this information is for you if: Your eye doctor has said that you have open-angle glaucoma,
More informationRelease of the 2013/14 Invitation to Tender
07 November 2013 Release of the 2013/14 Invitation to Tender The 2013/14 Invitation to Tender (2013/14 ITT) has been distributed today via the electronic tender (etender) system. If you do not receive
More informationChronic eye diseases. Title of section divider. What s new, and how GPs can help. Eg. Case Study 1. Dr Jesse Gale, ophthalmologist
Chronic eye diseases Title of section divider What s new, and how GPs can help Eg. Case Study 1. Dr Jesse Gale, ophthalmologist 1 Title of section divider Cataract Eg. Case Study 1. 2 Cataract - what s
More informationFinancial Disclosure. Prostaglandin Analogs (PGs) The Glaucoma Grab Bag: Practical Guidelines for Effective Glaucoma Therapy
The Glaucoma Grab Bag: Practical Guidelines for Effective Glaucoma Therapy Danica J. Marrelli, OD, FAAO University of Houston College of Optometry Financial Disclosure I have received I have received speaking
More information12.1 DRUGS ACTING ON THE EAR
12.1 DRUGS ACTING ON THE EAR Anti-inflammatory/anti-infective preparations These preparations usually contain a corticosteroid either alone or with an antibacterial agent. Betamethasone 0.1% ear, eye,
More informationOptometrists Formulary. Compiled and produced by Professor John Lawrenson Division of Optometry and Visual Science City University London
Optometrists Formulary Compiled and produced by Professor John Lawrenson Division of Optometry and Visual Science City University London August 2016 Contents Optometrists formulary background notes 1 Acetazolamide
More informationPHARMACOLOGY FOR OPTOMETRY
DEPARTMENT OF PHARMACOLOGY PHAR 3306 PHARMACOLOGY FOR OPTOMETRY COURSE OUTLINE Session 2, 2015 CRICOS Provider Code 00098G TABLE OF CONTENTS PHAR3306 Course Information... 3 Units of Credit (UOC)... 3
More informationKentucky Department for Medicaid Services. Drug Review Options
Kentucky Department for Medicaid Services Drug Review Options The following chart lists the agenda items scheduled and the options submitted for review at the March 18, 2010 meeting of the Pharmacy and
More informationThe Trust does not record electronically the number of patients who are treated by laser for a condition.
Ref: FOI/CAD/ID 3224 06 April 20 Please reply to: FOI Administrator Trust Management Maidstone Hospital Hermitage Lane Maidstone Kent ME 9QQ Email: mtw-tr.foiadmin@nhs.net Freedom of Information Act 2000
More informationDry Eye Prescribing Guidelines
Dry Eye Prescribing Guidelines Amendment History VERSION DATE AMENDMENT HISTORY V1.0 2011 Comments V1.1 2013 Updated V1.1 2017 Draft Updated Thealoz Duo replaces carmellose Optive in severe dry eye on
More informationOphthalmological preparations
Ophthalmological preparations Administration of eye preparations Preparations for the eye should be sterile when issued. Use of single-application containers is preferable; multiple-application preparations
More informationSupply should only occur if requesting signature is on approved list held by the issuing pharmacy
Trust Approved Drugs List March 2016 The following is the list of drugs that are approved by the EEAST Medicines Management Group for use by EEAST clinical staff. Pharmacies are advised that this is the
More informationThe healthiest place to live and work, by 2025
Quoracy 30/09/16 Cannock Chase Clinical Commissioning Group The healthiest place to live and work, by 2025 Joint CCG Formulary Working Group Friday 30 th September 2016 1.00pm 3.00pm Anglesey House, Rugeley,
More informationOphthalmic Immunomodulators Prior Authorization with Quantity Limit Program Summary
Ophthalmic Immunomodulators Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1,4 Agent Indication Dosage and Administration Restasis (cyclosporine ophthalmic emulsion)
More informationOcular Medication and Compliance
Ocular Medication and Compliance Consultant for Alcon Disclosures CECELIA KOETTING, OD FAAO VIRGINIA EYE CONSULTANTS VOA CONFERENCE NORFOLK 2018 Virginia Optometry License Generic vs Brand Name Every state
More informationDry Eye Syndrome Prescribing Guidelines
Dry Eye Syndrome Prescribing Guidelines Dry Eye Syndrome is a group of disorders of the ocular surface related to tear film abnormality, associated with ocular discomfort, visual symptoms and objective
More informationTA Number. TA Link. Annotation
Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed 16 02 2017 Title Formulary Status Section TA Number TA Link Annotation Anti-infective preparations Anti-inflammatory
More informationPharmaceutical Management Medicaid 2019
Pharmaceutical Management Medicaid 2019 Toll-free Contact Number: (888) 327-0671 Pharmacy Administration: (810) 244-1660 Introduction Pharmaceutical Management promotes the use of the most clinically appropriate,
More informationPHARMA-MEDIC SERVICES INC. POLICY MANUAL
PHARMA-MEDIC SERVICES INC. POLICY MANUAL SUBJECT: INDEX: P.5.a.iii Automatic-Therapeutic Substitution DATE: June 1/2011 REVISED: March 2, 2015., Feb 2017. PROCEDURE: 1. Long term care homes use the Manitoba
More informationJuly Formulary Policy
Formulary Policy July 2017 Responsible Committee: Quality Committee Date Effective: July 2017 Author: Rahinatu Amadu Supersedes: July 2016 Next Review Due: July 2018 Formulary Policy 2016-2018 1. INTRODUCTION
More informationSummary of the risk management plan (RMP) for Izba (travoprost)
EMA/14138/2014 Summary of the risk management plan (RMP) for Izba (travoprost) This is a summary of the risk management plan (RMP) for Izba, which details the measures to be taken in order to ensure that
More informationIOP measurements: 8.00 am (trough drug levels) and am (peak drug levels)(2 hours post dose)
This overview of 2% eye drops was presented by Dr. Ravin N. Das, at Hotel Satya Ashoka, on 19-6-2004 in place of Dr. H. S. Ray due to unforseen circumstances. This dinner meeting was sponsored by Cipla
More informationTechnology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta369
Ciclosporin for treating dry eye e disease that has not improved despite treatment with artificial tears Technology appraisal guidance Published: 16 December 2015 nice.org.uk/guidance/ta369 NICE 2018.
More informationGet a grip on your glaucoma Booklet 1
Information for Patients Glaucoma services Welcome! Get a grip on your glaucoma Booklet 1 Group-based Glaucoma information Course Session 1 What happens in session 1? Finding out what questions you have
More informationPRACTICAL APPROACH TO MEDICAL MANAGEMENT OF GLAUCOMA
PRACTICAL APPROACH TO MEDICAL MANAGEMENT OF GLAUCOMA DR. RAVI THOMAS, DR. RAJUL PARIKH, DR. SHEFALI PARIKH IJO MAY 2008 PRESENTER AT JDOS : DR. RAHUL SHUKLA T.N. SHUKLA EYE HOSPITAL TERMINOLOGY POAG: PRIMARY
More informationAdministration and Supply of Emergency Medicines
APPENDIX WHO CAN GIVE WHAT? Administration and Supply of Emergency Clinician Authorisation Key to Exemptions from legislation: NPP Non Parenteral POM. Can be given according to a protocol. 7 HMR 0, Schedule
More informationCompleted Clinical Research Trials Monte Dirks, M.D.
Completed Clinical Research Trials Monte Dirks, M.D. Monte Dirks, M.D. - Primary Investigator Norfloxacin -Merck (1986) Safety and efficacy of norfloxacin vs. tobramycin in the treatment of external ocular
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE. Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Glaucoma: diagnosis and management of chronic open angle glaucoma and ocular hypertension 1.1 Short title Glaucoma 2 Background
More informationGREAT WESTERN HOSPITALS NHS FOUNDATION TRUST
Attendees: Dr Ravi Chinthapalli (RC) (chair) Katherine Watkinson () (mins) Dr Rachel Hobson (RH) Paul Clarke (PC) Lisa King (LK) Formulary Working Group 17 th October 2013 1400 1510 Liden Meeting Room,
More informationGlaucoma: diagnosis and management (large print version)
Glaucoma: diagnosis and management (large print version) 1 November 2017 Recommendations People have the right to be involved in discussions and make informed decisions about their care, as described in
More informationOptometrists Formulary
1 Optometrists Formulary Compiled and Produced by Professor John Lawrenson, Division of Optometry and Visual Science City University London October 2012 2 Acetazolamide 9 Acetylcysteine 11 Aciclovir 13
More information10 Musculoskeletal and Joint Diseases
10 Musculoskeletal and Joint Diseases To be used in conjunction with NICE guidance, The British National Formulary for adults and/or children and British Society of Rheumatology guidelines and guidance
More informationAPPLICATION TO INCLUDE A PROCEDURE, PHARMACEUTICAL OR OTHER DATA COLLECTION INSTRUMENT IN THE UNIVERSITY REGISTER
Revised 09/99 APPLICATION TO INCLUDE A PROCEDURE, PHARMACEUTICAL OR OTHER DATA COLLECTION INSTRUMENT IN THE UNIVERSITY REGISTER Copies of the questions and instructions can be viewed by moving your mouse
More informationAbbreviated Class Update: Ophthalmics, Glaucoma agents. Month/Year of Review: August 2012 End date of literature search: June 2012
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPharmaceutical quality of reformulated bevacizumab as used in eye conditions in general.
The Royal College of Ophthalmologists 17 Cornwall Terrace, London. NW1 4QW. Telephone: 020-7935 0702 Facsimile: 020-7935 9838 Website: WWW.RCOPHTH.AC.UK PATRON HRH THE DUKE OF YORK, KG, KCVO, ADC The Royal
More informationCare homes - Homely remedies
Bulletin 72 August 2014 Community Interest Company Care homes - Homely remedies Care home staff have a recognised duty of care to be able to respond to minor symptoms experienced by residents. A homely
More informationDrug Prescribing Pattern & Adverse Drug Effects Of Anti Glaucoma Medication for Primary Glaucoma at Tertiary Care Hospital
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 11 Ver. III (Nov. 2017), PP 36-41 www.iosrjournals.org Drug Prescribing Pattern & Adverse Drug
More informationPharmacology of drugs acting on the eye. Prof. Hanan Hagar Pharmacology Unit College of Medicine
Pharmacology of drugs acting on the eye Prof. Hanan Hagar Pharmacology Unit College of Medicine ILOS Outline common routes of administration of drugs to the eye. Discuss the pharmacokinetics of drugs applied
More informationOHTS Baseline/Randomization Visit: BR
Page 1 of 5 2/28/5 OHBR02.00 Coordinating Center use only Rec d... Log d... Chk d... Entr d... Checklist Check when completed Before exam, patient first completes SF-36 Quality of Life Before exam, patient
More informationGenerics are Cheaper and Just as Effective
Disclosures Generics are Cheaper and Just as Effective Robert L. Stamper, MD UCSF Department of Ophthalmology No current pharmaceutical industry connections Data & Safety Monitor for Cypass - Chair - Transcend
More informationSerious Eye diseases, New treatments. Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist
Serious Eye diseases, New treatments Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist 5 major causes of loss of vision Cataracts Glaucoma Macular degeneration Retinal Vein occlusions
More informationLooking after Your Eyesight
Slide 1 GORING AND WOODCOTE MEDICAL PRACTICE PATIENT PARTICIPATION GROUP (PPG) Open Meeting Looking after Your Eyesight 14 April 2018 Slide 2 Agenda The New Practice Website Julia Beasley Ophthalmology
More informationconcentrate intravenous solution and other strong potassium solutions
Policy for the use of potassium chloride concentrate intravenous solution and other strong potassium solutions CLINICAL GUIDELINES ID TAG Policy for the use of potassium chloride Title: concentrate intravenous
More informationVolume 4; Number 6 May 2010
Volume 4; Number 6 May 2010 What s new this month: Local ophthalmologists have been working with PACEF to develop a formulary of eye preparations for the treatment of open angle and raised intra ocular
More informationVolume 4; Number 4 April 2010 PRESCRIBING GUIDANCE FOR HAY FEVER: SPRING / SUMMER 2010
Volume 4; Number 4 April 2010 PRESCRIBING GUIDANCE FOR HAY FEVER: SPRING / SUMMER 2010 PACEF Recommendations Recommended medicines remain the same as in recent years: Non-sedating antihistamines: generic
More informationMild NPDR. Moderate NPDR. Severe NPDR
Diabetic retinopathy Diabetic retinopathy is the most common cause of blindness in adults aged 35-65 years-old. Hyperglycaemia is thought to cause increased retinal blood flow and abnormal metabolism in
More informationThe use of eye drops and ointments in A&E
Janet Marsden MSc, BSc (Hons), RGN, MIMgt is Senior Lecturer, Manchester Metropolitan University, and Chair of the RCN Ophthalmic Forum Janet Marsden describes the various eye drops and ointments commonly
More informationAllergies Formulary
Self-care should be encouraged as. Self Care The self care forum states: Empowering people with the confidence information to look after themselves when they can, visit the GP when they need to, gives
More informationVolume 9; Number 3 March 2015 PRESCRIBING AND DISPENSING PREGABALIN FOR NEUROPATHIC PAIN
Arden and Greater East Midlands Commissioning Support Unit in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and
More informationLIST OF MEDICINE FOR OUTPATIENT DEPARTMENT (O.P.D) S. No.
Category C LIST OF MEDICINE FOR OUTPATIENT DEPARTMENT (O.P.D) S. 01 Dexamethasone +Chloramphenicol Eye drop 30000 02. 10000 Tobramycin 0.3% eye drop 03. Moxifloxacin Eye drop 7200 04. Hydroxypropyl Methyl
More informationAllergan s Blephamide (sulfacetamide/prednisolone ophthalmic ointment) 10%/0.2%, 3.5Gm tube
Allergan s Blephamide (sulfacetamide/prednisolone ophthalmic ointment) 10%/0.2%, 3.5Gm tube On Aug. 24, 2015, Allergan recalled three lots (86258 expires September 2017, 87189 December 2017 and 87514 February
More informationPOLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE. September 2011
POLICY FOR THE SAFE USE OF ORAL METHOTREXATE IN SECONDARY CARE September 2011 WHSCT Policy for the safe use of oral methotrexate in secondary care Page 1 of 8 Policy Title Policy for the safe use of oral
More informationSummary of Main Points from the Meeting held on Monday 11 th September 2017
Summary of Main Points from the Meeting held on Monday 11 th September 2017 2. Minutes and Summary Notes from last meeting The Minutes and Summary notes from the July 2017 Medicines Group meeting were
More informationUpdate on management of Anterior Uveitis
Update on management of Anterior Uveitis Parthopratim Dutta Majumder Senior Consultant, Department of Uvea & Intraocular Inflammation Medical Research Foundation, Sankara Nethralaya ABCD of Treating a
More informationNational Institute for Health and Clinical Excellence. Glaucoma. Guideline Consultation Comments Table. 29 September November 2008
National Institute for Health and Clinical Excellence Glaucoma Guideline Consultation Comments Table 29 September 2008 24 November 2008 Stat us Organisa tion Order no. Version Page no Line no/se ction
More informationDocument ref. no: Trust Policy and Procedure. PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy
Document ref. no: Trust Policy and Procedure PP(16)234 Prescribing, Dispensing and Administration of Methotrexate Policy For use in: For use by: For use for: Document owner: Status: All Clinical Areas
More information